FluoroPharma CEO Thijs Spoor to Be Interviewed Live Today on Clear Channel Business Talk Radio
Interview Scheduled at 2:05pm EDT / 12:05 pm MDT / 11:05am PDT on The Traders Network Radio Show, Hosted by Michael Yorba
MONTCLAIR, NJ–(Apr 2, 2014) – FluoroPharma Medical, Inc. (OTCQB: FPMI) (“FluoroPharma”), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today its CEO, Thijs Spoor, will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio’sThe Traders Network Show. Any interested parties may tune in and listen live via Clear Channel’s nationally syndicated iHeart Radio stream.
The live interview details are as follows:
Date: Wed, April 2, 2014
Start Time: 11:05am PDT | 12:05pm MDT | 2:05pm EDT (U.S.)
Network: Clear Channel
Station: DFW 1190AM KFXR
Show: The Traders Network
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true
About Clear Channel: Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. www.clearchannel.com.
About Michael Yorba: Mr. Yorba is the founder of Yorba Media and featured host on Clear Channel. For the past six years he has produced and hosted The Traders Network Show broadcasted live daily on Clear Channel DFW 1190AM KFXR from 1pm – 3pm CT, Monday-Friday.
Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps audience asking for more… shift your thinking and join us as we deliver “tomorrow’s ideas today” on Clear Channel’s The Traders Network Show.
About FluoroPharma Medical:
FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The company has licensed technology from the Massachusetts General Hospital in Boston.
The company’s goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.
FluoroPharma’s initial focus is the development of breakthrough PET imaging agents and is advancing two products in clinical trials for assessment of acute and chronic forms of coronary artery disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image brain tissue affected by Alzheimer’s disease and agents that could potentially be used for imaging specific cancers.
In addition to the United States, Europe and China, patents related to FluoroPharma’s portfolio of imaging compounds have been issued in Japan, Canada, Australia, Finland, Portugal, Ireland and Mexico.
For more information on the company, please visit: www.fluoropharma.com
A CommPro Worldwide PR Event
PR & Media Contact:
Matt Bird, CEO
C: +1 (646) 401-4499